[{"arm_notes": "", "treatment_id": null, "treatment_name": "Inoculate KD-414 or placebo intramuscularly 2 doses of 0.5 mL at intervals of 27 days.At 26 weeks after the second dose of the investigational product; 0.5 mL will be inoculated intramuscularly.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "0.5mL;2;days0-27 (>=20 years to <65 years and >=65 years)", "treatment_id": 703, "treatment_name": "Kd-414", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "0.5mL;1;26 weeks after 2nd dose (>=20 years to <65 years and >=65 years)", "treatment_id": 703, "treatment_name": "Kd-414", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Two doses of 0.5 mL KD-414 or placebo are administered intramuscularly at an interval of 27 days.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]